Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.008x

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hubei Biocause Pharmaceutical (000627) defensive interval to measure how many days the company can operate on defensive assets alone.

Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CareDx Inc NASDAQ:CDNA	0.014x
Intellect Design Arena Limited NSE:INTELLECT	0.027x
Xinjiang Communications Construction Group Co Ltd Class A SHE:002941	0.089x
Danya Cebus TA:DNYA	-0.046x
Lindab International AB ST:LIAB	0.071x
Suofeiya Home Collection Co Ltd SHE:002572	-0.038x
Procter & Gamble Health Limited NSE:PGHL	0.278x
Bafang Electric Suzhou Co Ltd SHG:603489	0.017x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Pharmaceutical market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	CN¥33.63 Billion ≈ $4.92 Billion	CN¥9.53 Billion ≈ $1.40 Billion	0.283x	+30.37%
2022-12-31	CN¥34.60 Billion ≈ $5.06 Billion	CN¥7.52 Billion ≈ $1.10 Billion	0.217x	+95.29%
2021-12-31	CN¥37.47 Billion ≈ $5.48 Billion	CN¥4.17 Billion ≈ $610.58 Million	0.111x	-82.02%
2020-12-31	CN¥34.59 Billion ≈ $5.06 Billion	CN¥21.42 Billion ≈ $3.13 Billion	0.619x	-25.61%
2019-12-31	CN¥34.35 Billion ≈ $5.03 Billion	CN¥28.60 Billion ≈ $4.19 Billion	0.833x	+44.56%
2018-12-31	CN¥26.01 Billion ≈ $3.81 Billion	CN¥14.98 Billion ≈ $2.19 Billion	0.576x	+3463.41%
2017-12-31	CN¥26.70 Billion ≈ $3.91 Billion	CN¥431.58 Million ≈ $63.15 Million	0.016x	+114.07%
2016-12-31	CN¥20.40 Billion ≈ $2.98 Billion	CN¥-2.34 Billion ≈ $-342.76 Million	-0.115x	-338.31%
2015-12-31	CN¥1.78 Billion ≈ $261.01 Million	CN¥-46.73 Million ≈ $-6.84 Million	-0.026x	-128.83%
2013-12-31	CN¥1.44 Billion ≈ $210.17 Million	CN¥130.53 Million ≈ $19.10 Million	0.091x	+48.97%
2012-12-31	CN¥1.54 Billion ≈ $224.96 Million	CN¥93.79 Million ≈ $13.72 Million	0.061x	+28.87%
2011-12-31	CN¥1.41 Billion ≈ $206.93 Million	CN¥66.95 Million ≈ $9.80 Million	0.047x	-66.23%
2010-12-31	CN¥1.60 Billion ≈ $234.43 Million	CN¥224.58 Million ≈ $32.86 Million	0.140x	+2.40%
2007-12-31	CN¥866.03 Million ≈ $126.73 Million	CN¥118.56 Million ≈ $17.35 Million	0.137x	-22.71%
2006-12-31	CN¥723.71 Million ≈ $105.90 Million	CN¥128.19 Million ≈ $18.76 Million	0.177x	+166.20%
2005-12-31	CN¥731.23 Million ≈ $107.00 Million	CN¥48.66 Million ≈ $7.12 Million	0.067x	-14.08%
2004-12-31	CN¥723.91 Million ≈ $105.93 Million	CN¥56.07 Million ≈ $8.20 Million	0.077x	+58.41%
2001-12-31	CN¥762.99 Million ≈ $111.65 Million	CN¥37.30 Million ≈ $5.46 Million	0.049x	--

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8526 Global

#2105 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.39 - CN¥2.60

All Time High

CN¥10.45